BOTOTLSJU
EIGR

Board of Trustees of The Leland Stanford Junior University’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Board of Trustees of The Leland Stanford Junior University’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,635
Closed -$1.46M – 25
2016
Q3 		$1.46M Buy
+3,635
New +$1.86M 0.16% 9

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Board of Trustees of The Leland Stanford Junior University's EIGR Position: Q4 2016 in Review

Board of Trustees of The Leland Stanford Junior University sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2016, closing a stake of 3,635 shares — an estimated $1.46M sold.

Board of Trustees of The Leland Stanford Junior University first reported a position in EIGR in Q3 2016 and held it in 1 quarter. The position peaked at $1.46M in Q3 2016. 51 funds tracked by Wall St. Rank hold EIGR as of Q4 2016.

  • Board of Trustees of The Leland Stanford Junior University reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Board of Trustees of The Leland Stanford Junior University sold 3,635 Eiger BioPharmaceuticals, Inc. shares in Q4 2016, an estimated $1.46M.
  • Board of Trustees of The Leland Stanford Junior University first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • Board of Trustees of The Leland Stanford Junior University's Eiger BioPharmaceuticals, Inc. position peaked at $1.46M in Q3 2016.
  • 51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2016.

Based on Board of Trustees of The Leland Stanford Junior University's 13F filing for Q4 2016, filed 10 Feb 2017.